our call. Thanks, Kevin. joining everyone, for afternoon, Good thanks and
development continue I will our comments today, pipeline product corporate as During the programs. advancing my and updates most promising provide we
and achieving and metrics data a will, of taking remission. the and a phase the will quarter three- ulcerative in endpoints, demonstrating all Kevin clinical of as both questions. improvement X and strong positive of conclude year, to we etrasimod for provide delivering this, always, Following statistically start significant a by first We've overwhelmingly four-domain primary had review on XXXX, financial secondary clinical colitis,
to as as well raise and development that continue potentially patients a strategy broad us we our Additionally, to believe expeditiously positions we capital possible. completed to deliver our in QX, thoughtful compounds best-in-class
of the catalysts over forward, expect XX amount XX significant Looking we to potential months. value next
initiating phase in the of ralinepag Specifically, second X multiple studies focused we're on 'XX. half for
on In program X etrasimod, planning program ulcerative in a phase are exciting toward a data well advancing colitis, the addition, we in Crohn's as following as robust disease.
us a building As by and cardiopulmonary building this ralinepag a compounds and supported additional company, around provides around business by clear a gastroenterology-hepatology business etrasimod. with anchored prioritization inside and currently focus Arena a
let's that, with with start So etrasimod.
failed primary colitis of trial XXX etrasimod oral OASIS in in we on reminder, the this Approximately of patients [ph]. disorders, potential anti-TNF inflammatory dose with As year, etrasimod X IBD. from a for once-a-day which well-characterized T-lymphocyte X-milligram mediated the ulcerative with one-third oral for we endpoints with March In XX% phase believe as week of XX, such option and previously to range for weeks. remission developed be [or has score patients upwards the patients achieved a an secondary physical results etrasimod of and in-house receiving in three-domain the Mayo the preferred having outstanding immune suffering is a clinical broad significance with patients of delivered of patients XX for integrin]
were to pleased meeting forward end the progress. on failed of using other and phase able thrilled to are results probably for considering these we're our and you the results, data to also suggesting with We We're in difficult-to-treat believe had We many prepare therapies, working our especially support FDA, to to X overall impressive phase with plan colitis. look We're are potential trial X were best-in-class ulcerative strong more these that actively of updating patients our product which we safety continue they these show such profile. patients. a results, that
colitis toward Moving on data forward Crohn's diligently light indications we the a colitis, ulcerative we also for disease. PBC, program further continue working that in liver, SXP detail positive a ducts. accumulate part back move patients Crohn's development X activity to the serve on as at We in Biliary a PBC XXXX. for this in the as trial. chronic broad of a of the view disease PBC, to disease lymphocyte disease, and on enroll be in time in need ulcerative focus resulting unmet And other the we're where X the path the to of to We or phase this etrasimod, on study. the destruction new concluding Cholangitis Crohn's significant has potential as in phase mediated pyoderma PBC. T liver forward treatment gangrenosum of lymphocytes program bile providing adding order to our in look the and in is will Primary having programs we In reduction cornerstone enrollment in believe
trial etrasimod, of offers data few will class multiple the clinical a are phase and on excited conviction the further that X long-term and it to growth we'll hep with believe going key tremendous a have and driver we and provides positive for this etrasimod company. medical product or be forward, us future and promise as the patients, to the We're treatment, potential in further To completed have best-in-SXP either meeting. GI in with safety who evaluate and summarize our broad utility. a indications, patients a evaluate etrasimod promise We present data ongoing at efficacy
our study on Now, dual a as X therapy. background where PAH these turning the majority most Group in treatment data the patients were X year you WHO know, of to population we positive of unprecedented of ralinepag, in delivered from line last top phase
is bar a best-in-disease designed treatment and, benefits potential importantly, broad is raised a With patient phase our PAH. elucidate that the in the belief ralinepag program ralinepag of the X product, for the of to population
treatment IV patients, can including through prostacyclins that's from benefit to any than oral access patients believe medication, important will phase refractory to to this result improved program X program. pharmacokinetics, closer to and across first-line As of a its a therapy be designed potency We extended enable and receptor other therapy the continuum add-on patients. the greater profile that
As for registrational phase and is two time a filing, to designed program a create the of program payers. and for the ralinepag an this differentiation study, benefits additionally, a providers to Each the and developed program of studies, will broad and a use drug. standalone be robust believe provide package, exercise of [Indiscernible] the comprehensive comprehensive ralinepag X non-registrational will capacity studies be registrational appropriate of trials evidence We clinical healthcare elucidate event global consisting is designed to reminder, a these to trial of study. be
of are ralinepag phase much than We're PAH comprehensive others benefits ralinepag program a X We have approach tend collectively, from we believe more broad taking for that, and confident a our appropriate forward the phase to in this which that We range therapy. patients, studies, best-in-disease because is the of rigorous believe elucidate are to three in will QX I've the to benefit programs done of X initiating a year. and will outlined, ralinepag three we this therapy. look program
advancement program pain the formerly of peripherally has [CBP] to known agonist significant broadly, in Crohn's on restricted, visceral new we treatment be full selective a Olorinab, this believe the [ph], a of highly potential and, to APD-XXX, as Moving pain.
X ralinepag phase toward and X ongoing path studies program some Crohn's complete phase in ralinepag important decisions positive enrollment the Given made prioritization data have and the colitis QX. substantial the planning to disease, now expect multiple our on the QX, prudent in the in the start of starting and proof-of-concept we phase etrasimod, and with resources. in forward We of for regulatory readout study overwhelming for etrasimod activities ulcerative X data
our update let So, a turn review. that, Kevin me for financial over with to it corporate and
